Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study. Issue 38 (September 2018)

• Record Type: Journal Article
• Authors: Xu, Xiao-Wei; Wu, Xiao-Xin; Chen, Ke-Da; Chen, Da-Zhi; Ou, Hui-Lin; Su, Jun-Wei; Yu, Hai-Ying; Yao, Hang-Ping; Li, Lan-Juan
• Other Names: Lin. Wenyu section editor.
• Is Part Of: Medicine. Volume 97:Issue 38(2018)
• Publication Date: 2018-09
• Subjects: chronic hepatitis C -- rapid virological response -- ribavirin -- sofosbuvir -- sustained virological response; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000012403
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Hepatitis C virus (HCV) is one of the most important virus as the cause of liver disease in China. The aim of the present study was to explore whether sofosbuvir and ribavirin-based treatment can cure patients with chronic hepatitis C in eastern China. We examined a cohort of HCV-monoinfected patients and 9 patients agreed to participate in our treatment and research. The patients were diagnosed with chronic hepatitis C with or without cirrhosis. Nine patients including 4 female and 5 male met the requirements for selection and were willing to participate in this experiment. Sofosbuvir and ribavirin-based treatment with or without interferon was given to the patients. Viral loads, cytokines, and chemokines were recorded during treatment and after treatment. After 2 weeks of sofosbuvir and ribavirin-based treatment, the viral load of patients decreased to limits of detection. Eight patients were cured. Patients had rapid virological response (RVR) with undetectable viral load at week 4 and sustained virological response (SVR). The interferon-inducible protein-10 (IP-10) decreased after the treatment. However, the patient with cirrhosis failed, as the virus reappeared during SVR4. At the same time, the IP-10 dramatically increased as the relapse of the HCV virus. In summary, the IP-10 has the potential to be the biomarker for the prognostic of HCV.